+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 0 - 18Years
All Genders
ID07168980

Intensive Chemotherapy and Early Rituximab Use for Aggressive Mature B-cell Non-Hodgkin Lymphoma in Children and Adolescents up to 18 Years

Led by Children's Cancer Group, China · Updated on 2026-06-04

87

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining intensive chemotherapy with early and frequent use of Rituximab can improve event-free survival EFS and overall survival OS in children and adolescents with aggressive mature B-cell Non-Hodgkin Lymphoma B-NHL. This study builds on previous research showing varying survival rates based on disease stage and treatment, aiming to enhance outcomes especially for high-risk patients. The study involves different treatment groups based on disease stage and risk factors. For early-stage disease, patients may receive 3 to 5 chemotherapy courses with intrathecal injections. Higher-risk groups receive more intensive chemotherapy cycles combined with multiple Rituximab doses, including six injections for the highest risk group, along with additional chemotherapy cycles for very high-risk patients. Treatments include various chemotherapy drugs such as Cyclophosphamide, Vincristine, Cytarabine, Doxorubicin, Prednisone, Ifosphamide, Etoposide, Methotrexate, and Vindelsine, administered according to detailed schedules. Participants will be closely monitored through scheduled follow-up visits to assess their response and any side effects. Researchers will measure event-free survival over three years as the primary outcome, with overall survival over the same period as a secondary outcome. The study will track treatment adherence, toxicity management, and use intrathecal injections for central nervous system involvement. Total participation duration extends up to or beyond three years, including ongoing evaluations to determine the effectiveness and safety of the treatment approach.

CONDITIONS

Brief Title

Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

Research Team

Y

Yi-jin Gao

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here